Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

12.05 +0.87 (+7.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,613,934
Open 11.13
Bid (Size) 11.25 (2)
Ask (Size) 13.00 (1)
Prev. Close 11.18
Today's Range 11.10 - 12.15
52wk Range 10.92 - 59.99
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Sage Therapeutics to Participate in Upcoming May Investor Conferences
From Sage Therapeutics
Via Business Wire

Performance

YTD
-46.40%
-46.40%
1 Month
-6.52%
-6.52%
3 Month
-45.65%
-45.65%
6 Month
-37.69%
-37.69%
1 Year
-77.43%
-77.43%

More News

Read More
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
Via Benzinga
Earnings Scheduled For February 14, 2024
Via Benzinga
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
Via Benzinga
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.